

Poor sleep and multiple sclerosis: associations with symptoms of multiple sclerosis and quality of life

Laura L Laslett ¹, Cynthia Honan ², Jason A Turner ², Baye Dagnew ^{1,3}, Julie A Campbell ¹, Tiffany K Gill ⁴, Sarah Appleton ^{4,5}, Leigh Blizzard ¹, Bruce V Taylor ¹, Ingrid van der Mei ¹

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2022-329227>).

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia

²School of Psychological Sciences, University of Tasmania, Launceston, Tasmania, Australia

³College of Medicine and Health Sciences, University of Gondar, Gondar, Amhara, Ethiopia

⁴Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia

⁵Flinders Health and Medical Research Institute (Sleep Health), Flinders University, Adelaide, South Australia, Australia

Correspondence to

Dr Laura L Laslett, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Laura.Laslett@utas.edu.au

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 2021; and Progress in MS Research, Hobart, 2022.

Received 14 March 2022

Accepted 7 June 2022

Published Online First 27 July 2022



© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Laslett LL, Honan C, Turner JA, et al. *J Neurol Neurosurg Psychiatry* 2022;**93**:1162–1165.

ABSTRACT

Background Sleep difficulties are common in people with multiple sclerosis (MS), but whether associations between poor sleep quality and quality of life are independent of MS symptoms, obesity and other MS-related factors remains unclear.

Methods Cross-sectional analyses of data from the Australian MS Longitudinal Study (n=1717). Sleep was assessed using the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale and International Restless Legs Syndrome Study Group Rating Scale; health-related quality of life using the Assessment of Quality-of-Life 8-D.

Results Poor sleep quality was common (67%), and more common than in community samples. Sleep measures clustered independently within MS symptoms. The clusters ‘fatigue and cognitive’, ‘feelings of anxiety and depression’, ‘pain and sensory’, were independently associated with poor sleep quality. Quality-of-Life utility scores were a clinically meaningful 0.19 units lower in those with poor sleep. Sleep quality, daytime sleepiness and restless leg syndrome were associated with reduced quality of life, independent of MS-related symptoms and body mass index.

Conclusion Poor sleep quality is common in MS and was strongly associated with worse health-related quality of life, independent of other MS symptoms and did not cluster with other common MS symptoms. Improving sleep quality may substantially improve quality of life in people with MS.

INTRODUCTION

Poor sleep quality is common in people with multiple sclerosis (PwMS) (up to 67%¹—more common than in the general community (33%–45%)).² It is associated with lower health-related quality of life (HRQoL),³ and higher mortality in the community.⁴ Risk factors for poor sleep in PwMS include disease duration⁵, disability,⁶ and MS symptoms, for example, fatigue, cognitive dysfunction, depression and anxiety.⁷ However, whether poor sleep remains associated with reduced HRQoL after considering MS symptoms remains unclear. As sleep quality is modifiable, improving sleep quality may result in clinically meaningful improvements in health outcomes.

This study (1) assessed whether sleep difficulties are prevalent and more common in PwMS than the general population, (2) examined how sleep related

to 13 common MS symptoms and (3) determined whether sleep quality is associated with HRQoL.

METHODS

Study samples

We used two surveys (2020) (total response rate 56%) from the Australian MS Longitudinal Study (AMSLS), a large representative cohort of Australians with MS.⁸ AMSLS was approved by the Tasmanian Health and Medical Human Research Ethics Committee (14183). All participants provided written informed consent.

Data from MAILES,⁹ an Australian community cohort of older men (n=826); and LIFE, a population-based German cohort of men (n=4420) and women (n=4864)¹⁰ were used as comparators.

Measurements

Pittsburgh Sleep Quality Index

Sleep quality over the last month was assessed using the Pittsburgh Sleep Quality Index (PSQI)¹¹ (range 0–21).

Epworth Sleepiness Scale

The ESS assessed level of daytime sleepiness across everyday situations,¹² scored on a 0–3 rating scale (range 0–24).

Restless Legs Rating Scale

The International Restless Legs Study Group Rating Scale¹³ (here, ‘Restless Legs Rating Scale’) assessed severity of restless legs symptoms and impact on sleep in the past week, on a 5-point scale (range 0–40).

MS Symptom Scores

Symptom severity over the previous 4 weeks (vs before they developed MS) of 13 common MS symptoms was assessed using MS Symptom Score (MSSymS),¹⁴ using a 0 (no problem) to 10 (worst possible symptom) Numeric Rating Scale (figure 1).

Assessment of quality of life

The Assessment of Quality of Life (AQoL-8D) is a comprehensive multiattribute utility instrument, which captures and assesses HRQoL, allowing billions of health states (2.4×10^{23}).¹⁵ Range is 0–1, where ‘0’ is the anchor point for death and ‘1’ is perfect health.¹⁵ The minimum clinically important




Figure 1 Dendrogram of hierarchical cluster analysis of how MS symptoms group together. Dendrogram presents information on how MS symptoms group together at various levels of similarity. On the left of the dendrogram, each symptom is considered as its own cluster. Horizontal lines extend up for each symptom and at various (dis) similarity values, these lines intersect with lines from other symptoms to form one line. Lines of symptoms continue to combine until all symptoms group together at the right of the dendrogram. Symptoms whose lines intersect towards the left of the figure are more closely related than those whose lines intersect further to the right. MS, multiple sclerosis.

difference (MCID) for the AQoL-4D is 0.06 utility points (95% CI 0.03 to 0.08).¹⁶

Sleep interference

Participants were asked ‘How often do sleep problems interfere with activities of daily living (ADLs)?’ and ‘how often do your sleep problems interfere with social functioning?’, scored on a 0–3 scale, with options ‘not during the past month’, ‘less than once a week’, ‘once or twice a week’ and ‘three or more times a week’.

Insomnia symptoms

Difficulty falling asleep, staying asleep, waking up too early and not being able to go back to sleep due to symptoms related to: (1) restless legs, (2) pain, (3) sensitivity to temperature, (4) needing to go to the toilet and (5) anxiety/stress or low mood were assessed. Responses were scored as for sleep interference.

Clinical and demographic measures

MS disability was measured by the Patient Determined Disease Steps scale¹⁷ (range 0 (normal)–8 (bedridden)). Education level, MS type, height and weight were self-reported.

Statistical analysis

Data were analysed using STATA V.17, with $p \leq 0.05$ considered statistically significant. Differences between good and poor sleepers and clinical populations were assessed using t-tests and χ^2 tests (online supplemental tables 1, 4 and 5). Effect sizes were estimated using Cohen’s d ¹⁸ (online supplemental table 5).

Hierarchical cluster analysis was used to assess whether and how the measures of sleep quality clustered with other MSSymS.¹⁹ We omitted individual sleep components and reran models as sensitivity analyses.

Associations between PSQI global score and AQoL-8D health utility score were assessed using linear regression and

automatically back-transformed using ‘linreg’, a user-defined STATA command. Final multivariate models were selected using backwards selection to remove components until all remaining terms were statistically significant ($p \leq 0.05$). Retained symptoms from the first model and sleep-related measures from the second model were included in models 3 and 4. Coefficients have been multiplied by 100 for consistency with other AMSLS publications.²⁰

Models were adjusted for confounders where appropriate. Regression diagnostics were run to ensure assumptions for linear regression were met.

RESULTS

Participant characteristics

Clinical and demographic characteristics of the study cohort are shown in online supplemental table 1.

Non-response bias analyses

Participants who completed both surveys were slightly older (+2.3 years; $p < 0.05$) and had a slightly longer MS duration (+1.2 years; $p < 0.01$). Thus, differences are unlikely to be clinically meaningful. There were no differences in sex or educational attainment.

Characterising sleep difficulties in the AMSLS cohort

Poor sleep quality (PSQI > 5) (68%), abnormal levels of daytime sleepiness (Epworth Sleepiness Scale, ESS ≥ 11 , 21%) and symptoms of restless legs (45%), difficulty falling asleep, staying asleep or inability to get back to sleep at ≥ 3 times weekly, sleep problems interfering with self-reported ADLs (16%) and social functioning (25%) at least weekly were common (online supplemental table 2). Sleep interference was more common in people with poor sleep quality than those with good sleep quality (38% (vs 8%) for ADLs and 33% (vs 6%) for social functioning). All assessments of sleep difficulties listed in online supplemental table 2 were more common in people with poor sleep quality by the PSQI (data not shown).

Relationship between sleep problems and common MS symptoms

Sleep problems did not cluster with other MS symptoms. Rather, all sleep problems clustered independently (figure 1). These results persisted when repeated without the ESS.

Factors associated with poor sleep quality

Being younger, overweight or obese, having a recent MS relapse, higher disability levels and three symptom clusters (‘pain and sensory’, ‘feelings of anxiety and depression’ and ‘fatigue and cognition’) were independently associated with poorer sleep quality in multivariate analyses (online supplemental table 3). Having a university education (vs primary/secondary school education only) was associated with lower PSQI scores (online supplemental table 3).

Comparison between PSQI scores in AMSLS participants versus population norms

In almost all comparisons, sleep quality in MS was worse in both males and females and most age groups (online supplemental tables 4 and 5). Effect sizes were large to very large (Cohen’s d) (online supplemental table 5).

Multiple sclerosis

Table 1 Assessment whether sleep-related measures were associated with health-related quality of life (measured with the overall AQoL-8D utility score), independent of other factors

	Univariate associations β (95% CI) n=1120	Multivariate model 1 symptoms and BMI only β (95% CI) n=1120	Multivariate model 2 sleep- related variables only β (95% CI) n=1120	Multivariate model 3 symptoms, BMI and PSQI β (95% CI) n=1120	Multivariate model 4 symptoms, BMI and sleep β (95% CI) n=1120
Sleep related measures (per unit increase)					
Pittsburgh Sleep Quality Index (0–21)	-2.77 (-3.04 to -2.51)	–	-1.90 (-2.17 to -1.63)	-1.26 (-1.47 to -1.04)	-1.08 (-1.31 to -0.86)
Epworth Sleepiness Scale (0–24)	-1.65 (-1.90 to -1.40)	–	-0.96 (-1.18 to -0.74)	–	-0.50 (-0.68 to -0.32)
Restless Legs Syndrome Score (0–40)	-1.11 (-1.22 to -0.99)	–	-0.63 (-0.75 to -0.51)	–	-0.21 (-0.31 to -0.11)
MS symptoms (0–10, per unit increase)					
Fatigue and cognitive symptoms	-5.47 (-5.89 to -5.06)	-1.31 (-1.81 to -0.80)	–	-0.88 (-1.35 to -0.40)	-0.71 (-1.19 to -0.23)
Feeling of anxiety and depression	-5.42 (-5.77 to -5.06)	-3.11 (-3.52 to -2.70)	–	-2.61 (-3.00 to -2.22)	-2.59 (-2.98 to -2.21)
Pain and sensory symptoms	-4.90 (-5.27 to -4.52)	-1.30 (-1.76 to -0.84)	–	-0.86 (-1.30 to -0.43)	-0.71 (-1.14 to -0.25)
Difficulties with walking, balance and spasticity	-4.31 (-4.68 to -3.95)	-1.22 (-1.65 to -0.80)	–	-1.38 (-1.78 to -0.99)	-1.31 (-1.70 to -0.91)
Bladder and bowel problems	-3.40 (-3.78 to -3.02)	–	–	–	–
Vision symptoms	-3.26 (-3.71 to -2.81)	–	–	–	–
Sexual symptoms	-2.80 (-3.12 to -2.48)	-0.38 (-0.67 to -0.08)	–	-0.42 (-0.70 to -0.15)	-0.36 (-0.61 to -0.09)
Demographics/disease factors					
BMI					
Healthy weight (18.5–24.9)	0.00 (Reference)	0.00 (Reference)	–	0.00 (Reference)	0.00 (Reference)
Overweight (25–29.9)	-2.96 (-5.83 to -0.09)	0.43 (-1.50 to 2.36)	–	0.80 (-1.00 to 2.60)	1.16 (-0.63 to 2.95)
Obese 1 (30–34.9)	-7.59 (-11.33 to -3.85)	-1.45 (-3.96 to 1.07)	–	-0.88 (-3.23 to 1.48)	-1.60 (-2.94 to 1.73)
Obese 2 (35–39.9)	-15.21 (-20.54 to -9.88)	-4.77 (-8.38 to -1.16)	–	-4.63 (-8.01 to -1.26)	-3.50 (-6.86 to -0.14)
Obese 3 (40+)	-15.15 (-21.14 to -9.17)	-6.05 (-10.09 to -2.00)	–	-4.75 (-8.54 to -0.97)	-3.87 (-7.64 to -0.10)
		Adjusted R ² =57.3%	Adjusted R ² =39.4%	Adjusted R ² =61.9%	Adjusted R ² =63.8%
Analysed using linear regression. Bold font indicates statistically significant results (p≤0.05). Coefficients have been multiplied by 100 to improve readability and to create consistency with other publications from the AMSLS cohort. AMSLS, Australian MS Longitudinal Study; AQoL, Assessment of Quality of Life; BMI, body mass index; PSQI, Pittsburgh Sleep Quality Index.					

Association between sleep problems and HRQoL

AQoL utility scores were 0.19 units lower in people with poor sleep (PSQI>5, mean 0.57, SD 0.2) compared with those with good sleep (PSQI≤5, mean 0.76, SD 0.18), p<0.001; double the upper limit of the MCID (0.08). Each unit increase in PSQI was associated with 0.019 reduction in AQoL-8D utility scores after adjustment for sleepiness (ESS) and restless legs (table 1, model 2), reducing to 0.0108 after further adjustment for symptoms and body mass index (BMI) (table 1, model 4).

All three sleep-related measures remained independently associated with AQoL-8D after taking other MS symptoms and BMI into account (table 1, model 4), with increased R² values when including sleep and symptoms (Table 1).

DISCUSSION

Poor sleep is very common in Australians living with MS (68%), and significantly more common than comparable population samples. Sleep did not cluster with recognised MS symptoms. Sleep-related variables were strongly, meaningfully and independently associated with poorer AQoL-8D utility scores. Therefore, poor sleep is associated with a substantial reduction in HRQoL independent of other common MS symptoms. Interventions that improve sleep may provide substantial benefits for PwMS.

Symptom clusters ‘feelings of anxiety and depression’, ‘pain and sensory’ and ‘fatigue and cognition’ were most strongly and independently associated with sleep quality, with modest effect sizes. Sleep complaints and depression/mood disorders²¹ are bidirectional longitudinally, and sleep complaints may be prodromal

to mood disorders,²² not just the reverse. Pain, fatigue and poor cognition can be temporally associated with each other in real time on the same day, but not across days.²³

Participants with poor sleep had average AQoL-8D utility scores 0.19 units lower than those with good sleep. Similarly, after accounting for other factors, every unit increase in PSQI was associated with a 0.0108-unit reductions in HRQoL, explaining up to 63.8% of variance in the overall AQoL-8D utility score.

Strengths include the large, representative⁸ national sample of PwMS and well-validated measures of correlates of HRQoL. Limitations include no objective measures of sleep, for example, polysomnography. Using wearables, for example, actigraphs²⁴ would add complementary information to sleep quality. Lastly, causal inferences about associations cannot be made from cross-sectional studies.

Sleep has a substantial impact on HRQoL, which warrants development of interventions to improve sleep. Interventions must include strategies to manage MS symptoms, sleep complaints and symptom-independent mechanisms of poor sleep. Further work will aid management of poor sleep and development of sleep interventions, including qualitative research, real-time symptom assessments using Apps and wearables, impact of medication use (including disease modifying therapies), and longitudinal studies examining factors associated with change in sleep.

CONCLUSION

Poor sleep quality did not cluster with common MS symptoms; and was strongly associated with HRQoL, independent of other

symptoms. Improving sleep quality and reducing symptom severity may substantially improve HRQoL in PwMS.

Twitter Laura L Laslett @DrLauraLaslett

Acknowledgements We thank Ms Carol Hurst and Dr Kirsty Hawkes for their expertise and attention to detail in collecting and cleaning the data for the MS Nurses and Sleep Study. We sincerely thank all participants of the Australian MS Longitudinal Study for their ongoing support and willingness to complete surveys.

Contributors LLL had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: CH and lvdM. Acquisition, analysis or interpretation of data: all authors. Drafting of the manuscript: LLL, BVT and lvdM. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: LLL. Obtained funding: BVT and lvdM.

Funding This study was funded by MS Research Australia.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by Tasmanian Health and Medical Human Research Ethics Committee (reference number 14183). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

Laura L Laslett <http://orcid.org/0000-0002-4336-0095>
 Cynthia Honan <http://orcid.org/0000-0001-5735-4270>
 Jason A Turner <http://orcid.org/0000-0002-2816-4459>
 Baye Dagnew <http://orcid.org/0000-0002-2397-5930>
 Julie A Campbell <http://orcid.org/0000-0002-1820-6758>
 Tiffany K Gill <http://orcid.org/0000-0002-2822-2436>
 Sarah Appleton <http://orcid.org/0000-0001-7292-9714>
 Leigh Blizzard <http://orcid.org/0000-0002-9541-6943>
 Bruce V Taylor <http://orcid.org/0000-0003-2807-0070>
 Ingrid van der Mei <http://orcid.org/0000-0001-9009-7472>

REFERENCES

- 1 Strober LB. Fatigue in multiple sclerosis: a look at the role of poor sleep. *Front Neurol* 2015;6:21.
- 2 Adams RJ, Appleton SL, Taylor AW, *et al.* Sleep health of Australian adults in 2016: results of the 2016 sleep health Foundation national survey. *Sleep Health* 2017;3:35–42.
- 3 Sarraf P, Azizi S, Moghaddasi AN, *et al.* Relationship between sleep quality and quality of life in patients with multiple sclerosis. *Int J Prev Med* 2014;5:1582.
- 4 Kwok CS, Kontopantelis E, Kuligowski G, *et al.* Self-reported sleep duration and quality and cardiovascular disease and mortality: a dose-response meta-analysis. *J Am Heart Assoc* 2018;7:e008552.
- 5 Vitkova M, Gdovinova Z, Rosenberger J, *et al.* Factors associated with poor sleep quality in patients with multiple sclerosis differ by disease duration. *Disabil Health J* 2014;7:466–71.
- 6 Vitkova M, Gdovinova Z, Rosenberger J, *et al.* Is poor sleep quality associated with greater disability in patients with multiple sclerosis? *Behav Sleep Med* 2018;16:106–16.
- 7 Ben Ari Shevil E, Johansson S, Ytterberg C, *et al.* How are cognitive impairment, fatigue and signs of depression related to participation in daily life among persons with multiple sclerosis? *Disabil Rehabil* 2014;36:2012–8.
- 8 Taylor BV, Palmer A, Simpson S, *et al.* Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. *Mult Scler* 2013;19:1627–31.
- 9 Grant JF, Martin SA, Taylor AW, *et al.* Cohort profile: the men androgen inflammation lifestyle environment and stress (MAILES) study. *Int J Epidemiol* 2014;43:1040–53.
- 10 Hinz A, Glaesmer H, Brähler E, *et al.* Sleep quality in the general population: psychometric properties of the Pittsburgh sleep quality index, derived from a German community sample of 9284 people. *Sleep Med* 2017;30:57–63.
- 11 Buysse DJ, Reynolds CF, Monk TH, *et al.* The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193–213.
- 12 Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991;14:540–5.
- 13 Abetz L, Ar buckle R, Allen RP, *et al.* The reliability, validity and responsiveness of the International restless legs syndrome Study Group rating scale and subscales in a clinical-trial setting. *Sleep Med* 2006;7:340–9.
- 14 Zhang Y, Taylor BV, Simpson S, *et al.* Validation of 0–10 MS symptom scores in the Australian multiple sclerosis longitudinal study. *Mult Scler Relat Disord* 2019;39:101895.
- 15 Richardson J, Iezzi A, Khan MA, *et al.* Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument. *Patient* 2014;7:85–96.
- 16 Hawthorne G, Osborne R. Population norms and meaningful differences for the assessment of quality of life (AQoL) measure. *Aust N Z J Public Health* 2005;29:136–42.
- 17 Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. *Neurology* 1995;45:251–5.
- 18 Cohen J. *Statistical power analysis for the behavioral sciences*. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
- 19 Chen J, Taylor B, Palmer AJ, *et al.* Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. *Mult Scler* 2019;25:994–1004.
- 20 Zhang Y, Taylor BV, Simpson S, *et al.* Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype. *Mult Scler* 2021;27:1262–75.
- 21 Fang H, Tu S, Sheng J, *et al.* Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. *J Cell Mol Med* 2019;23:2324–32.
- 22 Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. *J Psychiatr Res* 2003;37:9–15.
- 23 Kratz AL, Murphy SL, Braley TJ. Pain, fatigue, and cognitive symptoms are temporally associated within but not across days in multiple sclerosis. *Arch Phys Med Rehabil* 2017;98:2151–9.
- 24 Cederberg KLJ, Mathison BG, Schuetz ML, *et al.* Discrepancies between self-reported and device-measured sleep parameters in adults with multiple sclerosis. *J Clin Sleep Med* 2022;18:415–21.

Supplementary tables and figures

Supplementary Table 1: Demographic characteristics of AMSLS participants with good vs poor sleep quality, as assessed by the Pittsburgh Sleep Quality Index

	Total study sample (N=1717)	Good sleep quality PSQI≤5 (n=551) 32%	Poor sleep quality (PSQI>5) (n=1166) 68%	P value
Age (years), mean (SD)	57.7 (11.3)	58.2 (11.6)	57.4 (11.2)	0.20
MS duration since symptom onset (years), mean (SD)	22.4 (11)	22 (11)	22.6 (10.9)	0.36
MS duration since diagnosis (years), mean (SD)	16.8 (9.5)	17.2 (9.1)	16.7 (9.7)	0.36
Sex, female, N (%)	1368 (80)	418 (76)	950 (81)	0.01
Marital status				0.80
Single, never married	112 (11)	34 (10)	78 (11)	
Currently married / living as married	741 (73)	240 (73)	501 (73)	
Currently separated, divorced, widowed	161 (16)	55 (17)	106 (15)	
Currently on disease modifying therapy, N (%)	1710 (64)	549 (62)	1161 (65)	0.21
Relapse, last 12 months, N (%)	202 (15)	45 (10)	157 (17)	<0.001
MS onset type, N (%)				0.83
Relapse-onset MS	1024 (76)	336 (76)	688 (76)	
Progressive-onset MS	177 (13)	59 (13)	118 (13)	
Body mass index (kg/m ²), N (%)				0.007
Healthy BMI (18.5 -24.9)	570 (41)	207 (46)	363 (38)	
Overweight (25.0-29.9)	463 (33)	149 (33)	314 (33)	
Obese (≥30.0)	370 (26)	98 (22)	272 (29)	
Patient determined disease steps (PPDS) (0-8), N (%)				<0.001
No disability (PDDS score = 0)	331 (23)	151 (32)	180 (19)	
Mild disability (PDDS score = 1-2)	322 (23)	105 (23)	217 (23)	
Moderate disability (PDDS score= 3-5)	503 (35)	120 (26)	383 (40)	
Severe disability (PDDS score ≥6)	263 (19)	90 (19)	173 (18)	
Education attainment, N (%)				0.011
Primary and secondary school	441 (27)	125 (24)	312 (28)	
Occupational certificate / diploma	543 (33)	160 (31)	383 (35)	
University bachelor's degree or postgraduate degrees	645 (40)	233 (45)	412 (37)	
Individual MS symptoms (0-10), mean (SD)	n=1423	n=467	n=955	
Fatigue severity	5.1 (2.8)	3.9 (2.7)	5.6 (2.6)	<0.001
Walking difficulties	4.5 (3.3)	3.8 (3.5)	4.9 (3.2)	<0.001
Difficulty with balance	4.7 (3.1)	4.0 (3.2)	5.0 (3.0)	<0.001
Cognitive symptoms	3.7 (2.7)	2.8 (2.5)	4.2 (2.7)	<0.001
Pain	3.4 (3.1)	2.1 (2.6)	4.0 (3.1)	<0.001
Vision symptoms	2.3 (2.6)	1.8 (2.3)	2.6 (2.6)	<0.001

Bladder symptoms	4.3 (3.3)	3.6 (3.3)	4.6 (3.3)	<0.001
Bowel symptoms	3.3 (3.1)	2.5 (2.9)	3.7 (3.2)	<0.001
Sexual symptoms	3.8 (3.5)	2.8 (3.4)	4.2 (3.5)	<0.001
Feelings of depression	3.0 (2.8)	1.8 (2.3)	3.6 (2.9)	<0.001
Feelings of anxiety	3.1 (2.8)	1.8 (2.2)	3.7 (2.8)	<0.001
Sensory symptoms	4.2 (2.9)	3.1 (2.6)	4.7 (2.9)	<0.001
Spasticity	3.7 (3.1)	2.9 (2.9)	4.1 (3.1)	<0.001

Supplementary Table 2: Characterisation of sleep difficulties in the total study sample (n=1717)

	n (%)
Measure of sleep quality	
<i>Pittsburgh Sleep Quality Index total score (0-21)</i>	
Good sleep quality (≤ 5)	551 (32)
Poor sleep quality (> 5)	1166 (68)
<i>Epworth Sleepiness Scale total score (0-24)</i>	
Normal sleepiness (< 11)	1329 (77)
Abnormal sleepiness (≥ 11)	369 (21)
Potential causes of poor sleep	
<i>Restless Legs rating scale (0-40)</i>	
None (0)	614 (36)
Mild (1-10)	326 (19)
Moderate (11-20)	480 (28)
Severe / very severe (21-40)	288 (17)
<i>Difficulty falling asleep 3 or more times per week for any of the following reasons</i>	
Restless legs	258 (16)
Pain	293 (18)
Sensitivity to temperature	460 (28)
Needing to go to the toilet	576 (34)
Anxiety / stress or low mood	243 (15)
<i>Difficulty staying asleep 3 or more times per week for any of the following reasons</i>	
Restless legs	193 (12)
Pain	276 (17)
Sensitivity to temperature	416 (25)
Needing to go to the toilet	826 (49)
Anxiety / stress or low mood	196 (12)
<i>Unable to get back to sleep 3 or more times per week for any of the following reasons</i>	
Restless legs	129 (8)
Pain	218 (13)
Sensitivity to temperature	288 (17)
Needing to go to the toilet	488 (29)
Anxiety / stress or low mood	172 (10)
Potential results of poor sleep	
<i>How often do sleep problems interfere with activities of daily living?</i>	
Not during the past month	940 (55)
<once per week	289 (17)
Once per week or more	477 (16)
<i>How often do your sleep problems interfere with social functioning?</i>	
Not during the past month	946 (55)
<once per week	344 (20)
Once per week or more	254 (25)

Supplementary Table 3: Factors associated with the PSQI global score (0-21)

	β coefficient (95% CI)	β coefficient (95% CI) n=1095
	Univariate associations	Multivariate model
<u>Demographic and disease factors</u>		
Age (per year)	-0.004 (-0.01 to 0.003)	-0.03 (-0.05 to -0.004)
Sex		-
Female	Reference	
Male	-0.96 (-1.44 to -0.48)	
Relationship status		-
Married or living as married	Reference	
Separated, divorced or widowed	0.12 (-0.59 to 0.83)	
Single	0.06 (-0.77 to 0.89)	
Body mass index		
Healthy BMI (18.5 -24.9)	Reference	Reference
Overweight (≤ 25 -29.9)	0.65 (0.15 to 1.15)	0.59 (0.08 to 1.10)
Obese (≤ 30)	1.37 (0.83 to 1.92)	1.18 (0.61 to 1.74)
Education level		
Primary and secondary school	Reference	Reference
Occupational certificate / diploma	-0.11 (-0.64 to 0.43)	-0.06 (-0.63 to 0.51)
University degree (bachelor, postgraduate)	-0.88 (-1.38 to -0.38)	-0.97 (-1.51 to -0.43)
Disease course		-
Relapse onset MS	Reference	
Progressive onset MS	-0.36 (-1.02 to 0.31)	
PDDS		
No disability (0)	Reference	Reference
Mild disability (1-2)	1.30 (0.70 to 1.90)	0.94 (0.30 to 1.58)
Moderate disability (3-5)	2.15 (1.6 to 2.71)	1.93 (1.32 to 2.54)
Severe disability (≥ 6)	1.17 (0.54 to 1.8)	1.17 (0.42 to 1.92)
Currently using a disease modifying therapy	0.27 (-0.15 to 0.68)	-
MS relapse, past 12 months, doctor diagnosed	1.85 (1.22 to 2.47)	1.03 (0.39 to 1.66)
<u>7 Symptoms / Symptom clusters</u>		
	n=1401	n=1401
Fatigue and cognitive symptoms	0.65 (0.56 to 0.73)	0.21 (0.10 to 0.33)
Feeling of anxiety and depression	0.63 (0.55 to 0.7)	0.35 (0.26 to 0.45)
Pain and sensory symptoms	0.60 (0.52 to 0.68)	0.28 (0.19 to 0.38)
Vision symptoms	0.37 (0.29 to 0.45)	-
Difficulties with walking, balance and spasticity	0.32 (0.25 to 0.40)	§
Bladder and bowel problems	0.30 (0.23 to 0.37)	-
Sexual symptoms	0.24 (0.18 to 0.30)	-

Analysed using linear regression.

Bold font indicates statistically significant results ($p \leq 0.05$)

§The walking / balance / spasticity cluster has been removed from the multivariate model due to collinearity

Supplementary Table 4: Comparison of PSQI global scores between participants of the MAILES sleep study (2010-2012) and male participants in the Australian MS Longitudinal Study (AMSLS)

Age group	MAILES 2010-2012		AMSLS 2020		Difference	p
	n	mean \pm SD	n	mean \pm SD		
35-54 years	293	5.97 \pm 3.38	103	6.95 \pm 3.69	0.98	0.008
55-64 years	265	5.82 \pm 3.39	111	7.40 \pm 3.86	1.58	<0.001
65-74 years	182	5.81 \pm 3.69	95	7.46 \pm 3.72	1.65	<0.001
75+ years	86	7.38 \pm 4.21	36	6.47 \pm 3.89	-0.91	0.170
Total	826	6.03 \pm 3.57	345	7.19 \pm 3.77	1.16	<0.001

Source: Personal communication, Dr Tiffany Gill, 2021.

Supplementary Table 5: Comparison of PSQI global scores between participants in the Leipzig Center for Civilization Diseases (LIFE) study¹⁰ and the Australian MS Longitudinal Study (AMSLS)

Age group	Males							Females						
	LIFE 2017		AMSLS 2020		Diff- erence	Cohen's d	p	LIFE 2017		LIFE 2020		Diff- erence	Cohen's d	p
n	mean ± SD	n	mean ± SD	n				mean ± SD	n	mean ± SD	n			
<39 yrs	255	3.86 ± 2.69	12	5.83 ± 3.13	1.97	-0.68	0.051	254	4.21 ± 2.76	93	8.24 ± 4.27	4.03	-1.12	<0.001
40-49 yrs	1180	4.40 ± 2.85	47	6.70 ± 3.82	2.30	-0.68	<0.001	1410	4.93 ± 3.39	273	8.15 ± 4.01	3.22	-0.87	<0.001
50-59 yrs	990	4.51 ± 3.04	104	7.39 ± 4.12	2.88	-0.80	<0.001	1184	5.91 ± 3.71	419	8.31 ± 4.15	2.40	-0.61	<0.001
60-69 yrs	1114	4.33 ± 3.11	111	7.67 ± 3.41	3.34	-1.02	<0.001	1237	5.67 ± 3.56	393	8.33 ± 4.42	2.66	-0.66	<0.001
>70 yrs	881	4.42 ± 3.08	75	6.73 ± 3.81	2.31	-0.67	<0.001	779	6.31 ± 3.70	190	7.82 ± 4.20	1.51	-0.38	<0.001
All ages	4420	4.38 ± 3.00	349	7.19 ± 3.78	2.81	-0.82	<0.001	4864	5.54 ± 3.58	1368	8.21 ± 4.21	2.67	-0.68	<0.001

Total sample

Age group	LIFE 2017		AMSLS 2020		Diff- erence	Cohen's d	p
	n	mean ± SD	n	mean ± SD			
<39 yrs	509	4.04 ± 2.73	105	7.96 ± 4.21	3.92	-1.10	<0.001
40-49 yrs	2590	4.69 ± 3.17	320	7.94 ± 4.01	3.25	-0.90	<0.001
50-59 yrs	2174	5.28 ± 3.49	523	8.12 ± 4.15	2.84	-0.74	<0.001
60-69 yrs	2351	5.03 ± 3.42	504	8.18 ± 4.22	3.15	-0.82	<0.001
>70 yrs	1660	5.31 ± 3.51	265	7.51 ± 4.11	2.20	-0.58	<0.001
All ages	9284	5.00 ± 3.37	1717	8.00 ± 4.15	3.00	-0.79	<0.001

Bold font indicates statistically significant results ($p \leq 0.05$)

Effect sizes (Cohen's d) are medium >0.5 , large >0.8 and very large >1.2 ¹⁸